Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling
Pharmacological Research · 2026-12 · 234 · 109698
DOI: 10.1016/j.phrs.2026.109698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2026-12. Verfasst von Chengjun Yao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Key Laboratory of Mec…. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The contribution of polyol metabolism to pathological bone remodeling remains incompletely understood. Here, we examined its role in osteoclastogenesis and evaluated the skeletal effects of epalrestat, a clinically approved aldose reductase inhibitor. Exploratory single-cell analysis of two human femoral-head specimens suggested greater macrophage-associated polyol-pathway activity in the osteoporosis specimen. In primary bone marrow-derived macrophages, silencing of Akr1b3 and Sord produced opposing effects on osteoclast differentiation. Epalrestat suppressed RANKL-induced osteoclastogenesis and attenuated bone loss in diabetic, ovariectomy-induced, and inflammatory mouse models under early-intervention regimens. Mechanistic analyses showed improved NADPH/NADP⁺ and GSH/GSSG balance, reduced oxidative stress, and attenuated cytosolic and mitochondrial Ca²⁺ signals and Ca²⁺ oscillations. Genetic and osmotic-compensation experiments further supported a model in which intracellular sorbitol contributes to the osmotic regulation of Ca²⁺ oscillations. Additional findings included reduced inflammation in osteolysis and arthritis models, altered macrophage polarization, and partial preservation of bone marrow vascular features. Together, these findings connect glucose metabolism with redox and Ca²⁺ regulation during osteoclast differentiation and provide a rationale for further evaluation of epalrestat in skeletal disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Key Laboratory of Mechanism Research and Precision Repair of Orthopaedic Trauma and Aging D…
- Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Electronic address: caizimin626@163.com.
- Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Electronic address: 18857428525@163.com.
- School of Stomatology, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: 202212211601001@zcmu.edu.cn.
- Department of Orthopaedic Surgery, Ningbo Medical Center Li Huili Hospital Affiliated to Ningbo University, Ningbo, China. Electronic address: ningbolijie@zju.edu.cn.
- Department of Orthopaedic Surgery, Ningbo Medical Center Li Huili Hospital Affiliated to Ningbo University, Ningbo, China. Electronic address: cbh0508@sina.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yao, C., Cai, Z., Song, H., Xue, Q., Cai, B., He, W., Kong, X., Yang, T., Jin, J., Li, J., Chen, B., Zhao, F., Chen, J., Chen, J., & Liu, J. (2026). Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling. Pharmacological Research, 234, 109698. https://doi.org/10.1016/j.phrs.2026.109698
Vancouver
Yao C, Cai Z, Song H, Xue Q, Cai B, He W, et al. Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling. Pharmacological Research. 2026;234:109698. doi:10.1016/j.phrs.2026.109698
BibTeX
@article{Yao2026,
author = {Yao, Chengjun and Cai, Zimin and Song, Haixin and Xue, Qize and Cai, Bohan and He, Wenyao and Kong, Xiangxi and Yang, Tao and Jin, Jiayan and Li, Jie and Chen, Binhui and Zhao, Fengdong and Chen, Jia and Chen, Jian and Liu, Junhui},
title = {Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling},
journal = {Pharmacological Research},
year = {2026},
volume = {234},
pages = {109698},
doi = {10.1016/j.phrs.2026.109698}
}
EUVIMED